Literature DB >> 3104546

Gonadal function after surgery and chemotherapy in men with stage II and III nonseminomatous testicular tumors.

J M Nijman, H Schraffordt Koops, J Kremer, D T Sleijfer.   

Abstract

The gonadal functions were studied in 54 patients with disseminated nonseminomatous testicular tumors who had been subjected to combination chemotherapy (cisplatin, vinblastine, and bleomycin [PVB]) and surgery (hemiorchiectomy, retroperitoneal lymph node dissection or removal of retroperitoneal residual tumor after chemotherapy) and in 17 patients with a stage I tumor subjected to hemiorchiectomy exclusively. In the patients treated with chemotherapy, the plasma testosterone levels remained at the lower limit of normal and the luteinizing hormone (LH) levels remained elevated for 2 years after completion of treatment. The follicle-stimulating hormone (FSH) levels also remained significantly elevated, but showed a tendency to decrease after 2 years. Semen analysis was performed in 25 patients; of the other patients, 18 had no antegrade ejaculation, eight had undergone a vasectomy and three patients did not cooperate. Before treatment, 72% of the patients showed azoo- or oligozoospermia; 2 years after discontinuation of the chemotherapy, 48% had azoo- or oligozoospermia while 28% had more than 60 X 10(6) spermatozoa/mL. However, interestingly the proportion of patients with azoospermia had increased from 4% to 28%. In the course of this study, eight pregnancies occurred; one ended in an early spontaneous abortion; the other seven pregnancies ran an uncomplicated course. Seven healthy children were born. In 17 patients with a stage I tumor treated by hemiorchiectomy only, the testosterone, LH and FSH levels were also observed for 2 years; until 2 years after treatment, the testosterone levels remained lower and the FSH levels remained higher than normal. Insufficiency of the Leydig's cells in the unaffected gonad appeared to be responsible for the altered hormone concentrations in the blood.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104546     DOI: 10.1200/JCO.1987.5.4.651

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

Review 1.  Comparative tolerability of chemotherapy regimens for germ cell cancer.

Authors:  S Culine; J P Droz
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 2.  Effects of cancer and anti-neoplastic treatment on the human testicular function.

Authors:  A De Palma; E Vicari; I Palermo; R D'Agata; A E Calogero
Journal:  J Endocrinol Invest       Date:  2000-11       Impact factor: 4.256

3.  Fertility in the testicular cancer patient.

Authors:  M Carter
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

Review 4.  Preventable causes of male infertility.

Authors:  S T Thompson
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

5.  Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.

Authors:  E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; D F Bajorin; J P Donohue; J D Habbema
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

6.  Long-term effects on sexual function and fertility after treatment of testicular cancer.

Authors:  J T Hartmann; C Albrecht; H J Schmoll; M A Kuczyk; C Kollmannsberger; C Bokemeyer
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

7.  A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours.

Authors:  Ciara Conduit; Wei Hong; Felicity Martin; Benjamin Thomas; Nathan Lawrentschuk; Jeremy Goad; Peter Grimison; Nariman Ahmadi; Ben Tran; Jeremy Lewin
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.